Abstract: A system and method for processing a plurality of medical images using a plurality of clinical applications. A current study is received by a first server, the current study having first image series metadata. The first server can determine, based on several different techniques, that the current study is in progress. The system and method generates an assembled study set comprising the current study that is processed using a clinical application, the current study having a first series and a second series.

Abstract: Gel compositions are provided that can be utilized as carriers for beneficial agents when injected into a subject and which can provide sustained release of the beneficial agent over time. In particular, gel compositions containing an agent that renders the composition thixotropic to facilitate injection of the gel into a subject with minimal discomfort to the subject are described.

Abstract: Injectable depot compositions are provided that include a polymer matrix having a plurality of bioerodible, biocompatible polymers wherein each polymer of the plurality of polymers has a specified average molecular weight, and the polymer matrix has a broad molecular weight distribution of the plurality of polymers; a solvent having a miscibility in water of less than or equal to 7 wt % at 25° C., in an amount effective to plasticize the polymer and form a gel therewith; and a beneficial agent. The compositions have substantially improved shear thinning behavior and reduced injection force, rendering the compositions readily implanted beneath a patient's body surface by injection.

Abstract: The invention provides sulfated oxidised regenerated cellulose compounds, sulfated alginates, and the salts and hydrates thereof. The compounds are obtained by sulfation of oxidised regenerated cellulose with sulfur trioxide. The invention also provides pharmaceutical compositions comprising the compounds, in particular compositions for the treatment of medical conditions mediated by a matrix metalloproteinases and anticoagulant pharmaceutical compositions.

Abstract: Methods and compositions for systemically or locally administering a beneficialagent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a prolonged duration of time. The compositions include a biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

Abstract: Injectable depot compositions with dual mechanisms of release rate control are provided for sustained beneficial agent delivery in a patient. The composition includes bioerodible particles and an injectable depot vehicle containing a bioerodible polymer in an organic solvent, for forming a bioerodible depot implant after administration to the patient. The bioerodible particles are dispersed in the depot vehicle and contain a beneficial agent and a release rate controlling agent retarding the release of the beneficial agent from the bioerodible particles and from the depot implant.

Abstract: Methods and compositions for systemically or locally administering a beneficial agent to a subject are described, and include, for example, implantable elastomeric depot compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a prolonged duration of time. The compositions include a biocompatible, elastomeric caprolactone copolymer, a biocompatible solvent having low water miscibility that forms an elastomeric viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

Abstract: A composition includes a viscous gel formed from a combination of a biodegradable polymer and a biocompatible solvent. The composition also includes a hydrophilic porogen, which may be incorporated in the viscous gel. The composition may form a porous scaffold in situ.

Abstract: A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.

Abstract: The present invention relates generally to compositions and methods for administering a biologically active agent, and more specifically to injectable non-aqueous suspensions.

Abstract: The present invention relates generally to compositions and methods for administering a biologically active agent, and more specifically to injectable non-aqueous suspensions.

Abstract: Methods and compositions for systemically or locally administering a beneficial agent to a subject are described, and include, for example, implantable elastomeric depot compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a prolonged duration of time. The compositions include a biocompatible, elastomeric polymer, a biocompatible solvent having low water miscibility that forms an elastomeric viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

Abstract: Methods and compositions for systemically or locally administering a beneficialagent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a prolonged duration of time. The compositions include a biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

Abstract: Drug delivery systems and kits are provided that release an anesthetic, such as bupivacaine, over a short duration. Methods of administering and preparing such systems are also provided. Drug delivery systems include a short duration gel vehicle and an anesthetic dissolved or dispersed in the gel vehicle. The gel vehicle comprises a low molecular weight bioerodible, biocompatible polymer and a water-immiscible solvent in an amount effective to plasticize the polymer and form a gel with the polymer. In some instances, a component solvent is used along with the water-immiscible solvent. An efficacy ratio, which is one way to measure the efficacy of a delivery system, can be controlled based on, for example, the construction of the gel vehicle to achieve a desired release profile.

Abstract: Injectable depot compositions are provided that include a polymer matrix having a plurality of bioerodible, biocompatible polymers wherein wherein each polymer of the plurality of polymers has a specified weight average molecular weight; and the polymer matrix has a broad molecular weight distribution of the plurality of polymers; a solvent having a miscibility in water of less than or equal to 7 wt. % at 25° C., in an amount effective to plasticize the polymer and form a gel therewith; and a beneficial agent. The compositions are have substantially improved the shear thinning behavior and reduced injection force, rendering the compositions readily implanted beneath a patient's body surface by injection.

Abstract: An airfoil having improved fatigue strength is disclosed. The airfoil comprises a tip, a root section, a platform, and an airfoil section located between the tip and the platform. The airfoil section has a leading edge and a trailing edge. A metallic coating is located along the leading edge and the trailing edge excluding a portion of the leading edge and the trailing edge located near the platform.